Stock Scorer

Bioregenx, Inc. (BRGX)

Bioregenx, Inc. reported revenue of 426.2K USD for the quarter ending 31 March 2026, down 17.3% from 515.1K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q1 '26 · ending 31 March 2026 426.2K -17.3%
Gross Profit Q1 '26 · ending 31 March 2026 348.3K -14.2%
Operating Income Q1 '26 · ending 31 March 2026 -49.8K —
Net Income Q1 '26 · ending 31 March 2026 -26.4K —
Cost of Revenue Q1 '26 · ending 31 March 2026 77.9K -28.6%
Operating Cash Flow Q1 '26 · ending 31 March 2026 26.6K -29.4%
Free Cash Flow Q4 '25 · ending 31 December 2025 66.6K —
Shares Outstanding Q1 '26 · ending 31 March 2026 969.2M +1.3%
EPS Q1 '26 · ending 31 March 2026 0.00 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 1.9M-1.2M-1.5M29.9K
20242024-12-31 2.3M-22.8M-23.1M-513.5K
20232023-12-31 3.4M-3.4M-3.6M-1.5M
20222022-12-31 42.2K-78.3K-78.3K—
20212021-12-31 198.6K-165.1K-96.9K—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q1 '262026-03-31426.2K
Q4 '252025-12-31385.6K
Q3 '252025-09-30507.8K
Q2 '252025-06-30446K
Q1 '252025-03-31515.1K
Q4 '242024-12-31460.5K
Q3 '242024-09-30596K
Q2 '242024-06-30734K
Q1 '242024-03-31549.5K
Q4 '232023-12-31678K
Q3 '232023-09-30794.5K
Q2 '232023-06-30863.3K
Q1 '232023-03-311.1M
Q4 '222022-12-318.9K
Q3 '222022-09-3011.3K
Q2 '222022-06-3014.3K
Q1 '222022-03-317.7K

Gross Profit Quarterly

PeriodEndingGross Profit
Q1 '262026-03-31348.3K
Q4 '252025-12-31318.8K
Q3 '252025-09-30426.4K
Q2 '252025-06-30352.5K
Q1 '252025-03-31406K
Q4 '242024-12-31322.7K
Q3 '242024-09-30481.6K
Q2 '242024-06-30469.9K
Q1 '242024-03-31384.2K
Q4 '232023-12-31378K
Q3 '232023-09-30571.2K
Q2 '232023-06-30598.3K
Q1 '232023-03-31763.9K

Operating Income Quarterly

PeriodEndingOperating Income
Q1 '262026-03-31-49.8K
Q4 '252025-12-31-935.7K
Q3 '252025-09-30-8.5K
Q2 '252025-06-30-107.3K
Q1 '252025-03-31-192.6K
Q4 '242024-12-31-18.3M
Q3 '242024-09-30-327.3K
Q2 '242024-06-30-1M
Q1 '242024-03-31-3.1M
Q4 '232023-12-31-211.6K
Q3 '232023-09-30-2.5M
Q2 '232023-06-30-544.6K
Q1 '232023-03-31-184.1K
Q4 '222022-12-31-5.5K
Q3 '222022-09-30-2.2K
Q2 '222022-06-30-33.3K
Q1 '222022-03-31-37.3K

Net Income Quarterly

PeriodEndingNet Income
Q1 '262026-03-31-26.4K
Q4 '252025-12-31-1M
Q3 '252025-09-30-80.6K
Q2 '252025-06-30-178.3K
Q1 '252025-03-31-266.9K
Q4 '242024-12-31-18.4M
Q3 '242024-09-30-394.9K
Q2 '242024-06-30-1.1M
Q1 '242024-03-31-3.2M
Q4 '232023-12-31-256.7K
Q3 '232023-09-30-2.5M
Q2 '232023-06-30-594.5K
Q1 '232023-03-31-229.8K
Q4 '222022-12-31-5.5K
Q3 '222022-09-30-2.2K
Q2 '222022-06-30-33.3K
Q1 '222022-03-31-37.3K

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q1 '262026-03-3177.9K
Q4 '252025-12-3166.9K
Q3 '252025-09-3081.4K
Q2 '252025-06-3093.5K
Q1 '252025-03-31109.1K
Q4 '242024-12-31137.8K
Q3 '242024-09-30114.4K
Q2 '242024-06-30264.2K
Q1 '242024-03-31165.4K
Q4 '232023-12-31300K
Q3 '232023-09-30223.3K
Q2 '232023-06-30265K
Q1 '232023-03-31311.7K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q1 '262026-03-3126.6K
Q4 '252025-12-3169.6K
Q3 '252025-09-30-71.6K
Q2 '252025-06-303.2K
Q1 '252025-03-3137.7K
Q4 '242024-12-31-11.4K
Q3 '242024-09-30-31.2K
Q2 '242024-06-30-177.3K
Q1 '242024-03-31-104.2K
Q4 '232023-12-31-245.6K
Q3 '232023-09-30-283.5K
Q2 '232023-06-30-649.2K
Q1 '232023-03-31-336.8K
Q4 '222022-12-31-4.4K
Q3 '222022-09-30-6.3K
Q2 '222022-06-30-33.1K
Q1 '222022-03-31-20.9K

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-3166.6K
Q3 '252025-09-30-77.6K
Q2 '252025-06-303.2K
Q1 '252025-03-3137.7K
Q4 '242024-12-31-11.4K
Q3 '242024-09-30-31.2K
Q2 '242024-06-30-177.3K
Q1 '242024-03-31-293.6K
Q4 '232023-12-31-245.6K
Q3 '232023-09-30-283.5K
Q2 '232023-06-30-649.2K
Q1 '232023-03-31-336.8K

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q1 '262026-03-31969.2M
Q3 '252025-09-30960.9M
Q2 '252025-06-30959.2M
Q1 '252025-03-31957M
Q3 '242024-09-30956.5M
Q2 '242024-06-30956.5M
Q1 '242024-03-31767.6M
Q3 '232023-09-30621.9M
Q2 '232023-06-30764.3M
Q1 '232023-03-31619M
Q3 '222022-09-30269.7M
Q2 '222022-06-30269.7M
Q1 '222022-03-31269.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q1 '262026-03-310.00
Q4 '252025-12-310.00
Q3 '252025-09-30-0.02
Q2 '252025-06-30-0.02
Q1 '252025-03-31-0.02
Q4 '242024-12-31-0.02
Q3 '242024-09-300.00
Q2 '242024-06-300.00
Q1 '242024-03-310.00
Q4 '232023-12-310.00
Q3 '232023-09-300.00
Q2 '232023-06-300.00
Q1 '232023-03-310.00
Q4 '222022-12-310.00